Retatrutide: A new drug for obesity and diabetes brings spectacular results

Retatrutide, a new drug under intense research, raises great hopes among patients and doctors around the world. Although it has not yet been approved for marketing by any regulatory agency, it is already referred to as the "Godzilla" of weight loss drugs. All thanks to the spectacular results of the largest clinical trial to date, which included over two thousand people with obesity and type 2 diabetes.

How does Retatrutide work?

Retatrutide is an innovative preparation that imitates the action of three key intestinal hormones: GLP-1, GIP and glucagon. These substances play an important role in regulating appetite, blood sugar levels and metabolism. Unlike other well-known drugs such as Wegovy or Mounjaro, Retatrutide not only acts on GLP-1 and GIP receptors, but also activates the glucagon receptor, which further increases the body's energy expenditure.

Spectacular weight loss

The 80-week clinical trial involved 2,047 people with obesity and type 2 diabetes from eight countries on four continents. Participants were divided into groups receiving different doses of Retatrutide or placebo, and were provided with dietary support and recommendations for physical activity.

The results turned out to be impressive. People taking the highest dose of the drug (12 mg) lost an average of 18.8 percent. body weight, and almost half of them reduced their weight by at least 20%. Every third patient lost weight by up to 25%. starting weight. For comparison, in the placebo group, only a few percent of participants achieved similar effects.

Benefits beyond weight loss

Retatrutide not only helps reduce body weight. Studies have shown that the drug significantly improves blood sugar control. As much as 72 percent patients taking the highest dose achieved HbA1c (average glycemia over the last 2-3 months) of 6.5%. or lower, which is considered the diagnostic threshold for type 2 diabetes. In the placebo group, only 29% achieved this result. participants.

In addition, Retatrutide had a beneficial effect on other cardio-metabolic risk factors, such as blood pressure, lipid profile and the level of C-reactive protein (hsCRP), which is a marker of inflammation.

Side effects and safety

Like any medicine, Retatrutide is not without side effects. The most frequently reported ailments were those related to the digestive tract, such as diarrhea (27-34% of patients) and nausea (14-28%). For comparison, in the placebo group these symptoms occurred in 13%. and 8 percent participants. There were also seven deaths during the study, but according to the investigators, they were not related to taking the drug.